Ghoneim Baker M, Elhindawy Khaled M Abdo, Fouad Fouad S, Ellil Mostafa H Abo, Shaker Ahmed A
Department of Vascular Surgery, Faculty of Medicine, Cairo University, Cairo, Egypt.
Int J Angiol. 2024 May 10;34(1):33-38. doi: 10.1055/s-0044-1786857. eCollection 2025 Mar.
The aim of this study was to assess the efficacy and safety of retrograde tibiopedal access as an alternative approach in cases of critical limb ischemia (CLI) when antegrade access has failed. A prospective study was conducted that included patients with CLI who underwent tibiopedal access after failed antegrade recanalization from January 2018 to June 2022. Follow-up was conducted at 6, 12, and 24 months. The primary outcomes evaluated were technical success rate and primary patency. Secondary outcomes included complication rate, mortality rate, and limb salvage rate (LSR). Forty-eight patients had CLI and Trans Atlantic Inter-Society Consensus infrainguinal lesions. The retrograde approach was used through the anterior tibial artery in 28 patients (58%), the posterior tibial artery in 18 patients (37.5%), and the peroneal artery in 2 patients (4.5%). Technical success was achieved in 90% of patients (43 patients). There was a significant increase in the anklebrachial index after the procedure with a mean follow-up of 22 months. Twenty-two months primary patency rate was 85.2%, while secondary patency rate was 100% and LSR was 96%, respectively. There was no mortality in the series. Retrograde tibiopedal approach is an alternative option for managing peripheral arterial disease and CLI. This method offers another means of crossing lesions when antegrade access failed, and the intervention can be completed either in an antegrade or retrograde approach. As the retrograde approach does not impact access site, considered a feasible safe treatment alternative which increase the success rate of endovascular treatment.
本研究的目的是评估在顺行入路失败时,逆行胫足部入路作为治疗严重肢体缺血(CLI)的替代方法的有效性和安全性。进行了一项前瞻性研究,纳入了2018年1月至2022年6月期间顺行再通失败后接受胫足部入路的CLI患者。在6个月、12个月和24个月时进行随访。评估的主要结局是技术成功率和原发性通畅率。次要结局包括并发症发生率、死亡率和肢体挽救率(LSR)。48例患者患有CLI和跨大西洋跨学会共识(TASC)下肢病变。28例患者(58%)通过胫前动脉采用逆行入路,18例患者(37.5%)通过胫后动脉,2例患者(4.5%)通过腓动脉。90%的患者(43例)实现了技术成功。术后踝肱指数显著增加,平均随访22个月。22个月时原发性通畅率为85.2%,继发性通畅率为100%,LSR分别为96%。该系列中无死亡病例。逆行胫足部入路是治疗外周动脉疾病和CLI的一种替代选择。当顺行入路失败时,这种方法提供了另一种跨越病变的手段,并且干预可以通过顺行或逆行方式完成。由于逆行入路不影响入路部位,被认为是一种可行的安全治疗选择,可提高血管内治疗的成功率。